文献速递肿瘤 PET/CT

[18F]FAPI-42与[18F]FDG PET/CT在喉鳞状细胞癌评估中的头对头比较

Head-to-head comparison of [18F]FAPI-42 and [18F]FDG PET/CT in the evaluation of laryngeal squamous cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-08

前瞻性纳入21例病理证实的喉鳞状细胞癌患者,均于1周内完成[18F]FDG与[18F]FAPI-42 PET/CT。FAPI-42对原发灶阳性检出率更高,T分期诊断效能更优,并可改变部分患者总体分期;以35% SUVmax(FDG)或40% SUVmax(FAPI-42)为阈值勾画肿瘤体积与增强CT高度一致。作者认为FAPI-42 PET/CT可能是有前景的显像方法,其远处转移评估价值需进一步研究。

要点

  • FAPI-42原发灶阳性检出率100%,FDG为85.7%。
  • FAPI-42对T分期诊断效能95.3%,高于FDG的57.1%(P=0.021)。
  • FAPI-42使4/21例(19.0%)N分期降期,与病理一致;总体分期改变10/21例(5例升期、5例降期)。

核心结论

  • [18F]FAPI-42在肿瘤检测、分期及原发灶勾画方面优于[18F]FDG,提示[18F]FAPI-42 PET/CT可能作为喉鳞状细胞癌检测与分期的有前景显像方法。
  • 其远处转移评估价值需进一步研究。

研究设计与样本

  • 前瞻性纳入2024年1月至10月病理证实的喉鳞状细胞癌患者21例。
  • 所有患者均在1周内完成[18F]FDG与[18F]FAPI-42 PET/CT。
  • 比较原发灶及淋巴结的SUVmax与视觉评估,并比较FDG PET、FAPI-42 PET与增强CT勾画的肿瘤体积。

主要发现

  • [18F]FAPI-42 PET/CT原发灶阳性检出率100%,[18F]FDG为85.7%。
  • 原发灶侵犯视觉评估中,[18F]FAPI-42在9/21例(42.9%)优于[18F]FDG,在1例(4.8%)劣于[18F]FDG,均经病理证实。
  • [18F]FAPI-42 PET/CT对T分期的诊断效能95.3%,高于[18F]FDG PET/CT的57.1%(P=0.021)。
  • [18F]FAPI-42相对[18F]FDG使4/21例(19.0%)N分期降期,与病理一致。
  • [18F]FAPI-42相对[18F]FDG改变10/21例总体分期,其中5例升期、5例降期。

关键数值与推荐

  • 原发灶阳性检出率:[18F]FAPI-42 100% vs [18F]FDG 85.7%。
  • T分期诊断效能:[18F]FAPI-42 95.3% vs [18F]FDG 57.1%(P=0.021)。
  • 肿瘤体积勾画阈值:35% SUVmax([18F]FDG)或40% SUVmax([18F]FAPI-42)时与增强CT高度一致。

临床怎么用

  • 作者认为[18F]FAPI-42 PET/CT可能作为喉鳞状细胞癌检测与分期的有前景显像方法。
  • 作者指出其远处转移评估价值需进一步研究。

局限性

  • 其远处转移评估价值需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the clinical utility of [18F]FAPI-42 PET/CT relative to [18F]FDG PET/CT for tumor detection and staging in laryngeal squamous cell carcinoma (LSCC) patients. METHODS: Patients with pathologically proven LSCC were prospectively enrolled. All patients underwent [18F]FDG and [18F]FAPI-42 PET/CT within 1 week. Primary tumor and lymph node showed by [18F]FDG and [18F]FAPI-42 PET/CT were compared by SUVmax and visual assessment. The primary tumor volumes derived from [18F]FDG PET, [18F]FAPI-42 PET, and contrast-enhanced CT were also compared. RESULTS: Twenty-one patients were included from January to October 2024. [18F]FAPI-42 PET/CT has a higher positive detection rate of primary tumor than [18F]FDG (100% vs. 85.7%). For visual assessment of primary tumor invasion, [18F]FAPI-42 was superior to [18F]FDG in 9 of 21 patients (42.9%) and inferior to [18F]FDG in 1 patient (4.8%), which was confirmed by pathology. The diagnostic efficacy of [18F]FAPI-42 PET/CT for T staging was higher than that of [18F]FDG PET/CT (95.3% vs. 57.1%, P = 0.021). [18F]FAPI-42 led to downstaging of N stage in 4 of 21 patients (19.0%) relative to [18F]FDG PET/CT, which was consistent with pathology. Compared with [18F]FDG, [18F]FAPI-42 PET/CT changed overall staging in 10 of 21 patients, with 5 patients being up-staged and 5 down-staged. When 35% SUVmax of [18F]FDG or 40% SUVmax of [18F]FAPI-42 was used as a threshold for delineating tumor volume, it was highly consistent with contrast-enhanced CT. CONCLUSION: [18F]FAPI-42 outperforms [18F]FDG in the tumor detection, staging, and the delineation of primary tumor, indicating that [18F]FAPI-42 PET/CT may serve as a promising imaging modality for detecting and staging patients with LSCC. Its value regarding distant metastases evaluation requires further investigation. TRIAL REGISTRATION: NCT06304155. https://clinicaltrials.gov/study/NCT06304155 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xia R, Wang X, Cheng J, et al. Head-to-head comparison of [18F]FAPI-42 and [18F]FDG PET/CT in the evaluation of laryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 40055207. doi:10.1007/s00259-025-07180-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。